Mittie Doyle's most recent trade in Avalo Therapeutics Inc was a trade of 4,654 Common Stock done at an average price of $20 . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 30 Jun 2026 | 4,654 | 51,776 | - | 20 | 93,080 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 2,875 | 125,750 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 30 Jun 2026 | 2,875 | 54,651 | - | 12.7 | 36,369 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 1,779 | 115,092 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 30 Jun 2026 | 1,779 | 56,430 | - | 8.0 | 14,303 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 23 Jun 2026 | 1,450 | 53,226 | - | 8.0 | 11,658 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2026 | 1,450 | 116,871 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 23 Jun 2026 | 1,450 | 51,776 | - | 18 | 26,100 | Common Stock |
| Cullinan Oncology Inc | Mittie Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 21,781 | 21,781 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 1,084 | 51,776 | - | 13.1 | 14,200 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2026 | 679 | 118,321 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 28 May 2026 | 679 | 47,122 | - | 16 | 10,864 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 28 May 2026 | 679 | 47,801 | - | 8.0 | 5,459 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 43,500 | 47,122 | - | 0 | Common Stock | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 15 May 2026 | 3,000 | 6,622 | - | 12.7 | 37,950 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 3,000 | 128,625 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.76 per share. | 15 May 2026 | 3,000 | 3,622 | - | 18.8 | 56,280 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 77,905 | 131,625 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 05 May 2026 | 77,905 | 81,527 | - | 12.6 | 985,498 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.20 per share. | 05 May 2026 | 44,944 | 32,695 | - | 21.2 | 952,669 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 28,650 | 119,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 05 May 2026 | 28,650 | 110,177 | - | 8.0 | 230,346 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 05 May 2026 | 27,538 | 82,639 | - | 18.0 | 496,405 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.41 per share. | 05 May 2026 | 19,015 | 13,680 | - | 22.4 | 426,050 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.88 per share. | 05 May 2026 | 10,058 | 3,622 | - | 22.9 | 230,127 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.65 per share. | 05 May 2026 | 5,000 | 77,639 | - | 19.7 | 98,251 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 05 May 2026 | 1,679 | 3,622 | - | 16 | 26,864 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 1,000 | 209,530 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 05 May 2026 | 1,000 | 4,622 | - | 12.7 | 12,650 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 05 May 2026 | 679 | 5,301 | - | 8.0 | 5,459 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 679 | 147,650 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 06 Apr 2026 | 3,970 | 7,592 | - | 12.7 | 50,221 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 3,970 | 210,530 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 06 Apr 2026 | 3,970 | 3,622 | - | 18.0 | 71,508 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 01 Apr 2026 | 679 | 3,622 | - | 16 | 10,864 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 679 | 148,329 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 01 Apr 2026 | 679 | 4,301 | - | 8.0 | 5,459 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.15 per share. | 16 Mar 2026 | 25,492 | 3,622 | - | 16.1 | 411,607 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 16 Mar 2026 | 19,500 | 23,122 | - | 12.7 | 246,675 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 19,500 | 214,500 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 5,992 | 149,008 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Mar 2026 | 5,992 | 29,114 | - | 8.0 | 48,176 | Common Stock |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 1,013 | 3,622 | - | 4.1 | 4,153 | Common Stock |
| Cullinan Oncology Inc | Mittie Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 79,456 | 79,456 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 234,000 | 234,000 | - | - | Stock Option (Right to Buy) |